Skip to main content
Erschienen in: Annals of Surgical Oncology 2/2021

16.07.2020 | Thoracic Oncology

Prognostic Impact of Smoking Period in Patients with Surgically Resected Non-small Cell Lung Cancer

verfasst von: Shinkichi Takamori, MD, PhD, Mototsugu Shimokawa, MD, PhD, Taichi Matsubara, MD, PhD, Naoki Haratake, MD, PhD, Ryo Toyozawa, MD, Naoko Miura, MD, PhD, Masafumi Yamaguchi, MD, PhD, Takashi Seto, MD, PhD, Tetsuzo Tagawa, MD, PhD, Tatsuro Okamoto, MD, PhD, Mitsuhiro Takenoyama, MD, PhD, Yoshihiko Maehara, MD, PhD, Masaki Mori, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

The pack-year index, which is calculated by multiplying a smoking period by the number of cigarette packs smoked per day, is frequently used to investigate the risk of developing lung cancer. Notably, however, whether the smoking period or the number of packs per day is more predictive of postoperative prognosis remains unclear in non-small cell lung cancer (NSCLC) patients who receive curative lung resection.

Patients and Methods

Initial screening included 2055 consecutive lung cancer patients who had underwent curative lung resection between 2000 and 2016 at a single center in Japan. Data from 1134 NSCLC patients with smoking history were ultimately analyzed. Time-dependent areas under the curve (AUCs) were used to compare diagnostic accuracy.

Results

On univariate analysis, the number of packs smoked per day was not a significant predictor of disease-free survival (DFS; p = 0.2387) or overall survival (OS; p = 0.1357). On multivariable analysis, smoking period was an independent predictor of DFS and OS (both p < 0.0001). Time-dependent smoking period AUCs were superior to those of number of packs smoked per day. On subgroup analyses, patients with a smoking period ≥ 40 years had significantly shorter DFS and OS than those with a smoking period of < 40 years, independent of sex, clinical stage, and histological type.

Conclusions

Smoking period was a significant prognostic indicator in NSCLC patients who underwent curative lung resection, which should be validated in further prospective and/or multicenter studies with large sample sizes.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.PubMedCrossRef Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.PubMedCrossRef
2.
Zurück zum Zitat Ettinger DS, Akerley W, Bepler G, et al. Non-small cell lung cancer. J Natl Compr Canc Netw. 2010;8(7):740–801.PubMedCrossRef Ettinger DS, Akerley W, Bepler G, et al. Non-small cell lung cancer. J Natl Compr Canc Netw. 2010;8(7):740–801.PubMedCrossRef
3.
Zurück zum Zitat Doll R, Hill AB. Smoking and carcinoma of the lung. Preliminary report. 1950. Bull World Health Organ. 1999;77(1):84–93. Doll R, Hill AB. Smoking and carcinoma of the lung. Preliminary report. 1950. Bull World Health Organ. 1999;77(1):84–93.
4.
Zurück zum Zitat Hecht SS. Tobacco smoke carcinogens and lung cancer. JNCI-J Ntl Cancer I. 1999;91(14):1194–210.CrossRef Hecht SS. Tobacco smoke carcinogens and lung cancer. JNCI-J Ntl Cancer I. 1999;91(14):1194–210.CrossRef
5.
Zurück zum Zitat Alberg AJ, Ford JG, Samet JM. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132(3 Suppl):29s–55s. Alberg AJ, Ford JG, Samet JM. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132(3 Suppl):29s–55s.
6.
Zurück zum Zitat Fujisawa T, Iizasa T, Saitoh Y, et al. Smoking before surgery predicts poor long-term survival in patients with stage I non-small-cell lung carcinomas. J Clin Oncol. 1999;17(7):208–-91.PubMedCrossRef Fujisawa T, Iizasa T, Saitoh Y, et al. Smoking before surgery predicts poor long-term survival in patients with stage I non-small-cell lung carcinomas. J Clin Oncol. 1999;17(7):208–-91.PubMedCrossRef
7.
Zurück zum Zitat Kawai H, Tada A, Kawahara M, et al. Smoking history before surgery and prognosis in patients with stage IA non-small-cell lung cancer–a multicenter study. Lung Cancer (Amsterdam, Netherlands). 2005;49(1):63–70.CrossRef Kawai H, Tada A, Kawahara M, et al. Smoking history before surgery and prognosis in patients with stage IA non-small-cell lung cancer–a multicenter study. Lung Cancer (Amsterdam, Netherlands). 2005;49(1):63–70.CrossRef
8.
Zurück zum Zitat Peto J. That the effects of smoking should be measured in pack-years: misconceptions 4. Br J Ccancer. 2012;107(3):406–07.CrossRef Peto J. That the effects of smoking should be measured in pack-years: misconceptions 4. Br J Ccancer. 2012;107(3):406–07.CrossRef
9.
Zurück zum Zitat Shiono S, Katahira M, Abiko M, Sato T. Smoking is a perioperative risk factor and prognostic factor for lung cancer surgery. Gen Thora Cardiovasc Surg. 2015;63(2):93–8.CrossRef Shiono S, Katahira M, Abiko M, Sato T. Smoking is a perioperative risk factor and prognostic factor for lung cancer surgery. Gen Thora Cardiovasc Surg. 2015;63(2):93–8.CrossRef
10.
Zurück zum Zitat Hanagiri T, Oka S, Takenaka S, et al. Results of surgical resection for patients with large cell carcinoma of the lung. Int J Surg (London, England). 2010;8(5):391–4.CrossRef Hanagiri T, Oka S, Takenaka S, et al. Results of surgical resection for patients with large cell carcinoma of the lung. Int J Surg (London, England). 2010;8(5):391–4.CrossRef
11.
Zurück zum Zitat Remen T, Pintos J, Abrahamowicz M, Siemiatycki J. Risk of lung cancer in relation to various metrics of smoking history: a case-control study in Montreal. BMC Cancer. Dec 19 2018;18(1):1275. Remen T, Pintos J, Abrahamowicz M, Siemiatycki J. Risk of lung cancer in relation to various metrics of smoking history: a case-control study in Montreal. BMC Cancer. Dec 19 2018;18(1):1275.
12.
Zurück zum Zitat Asamura H, Hishida T, Suzuki K, et al. Radiographically determined noninvasive adenocarcinoma of the lung: survival outcomes of Japan Clinical Oncology Group 0201. J Thorac Cardiovasc Surg. 2013;146(1):24–30.PubMedCrossRef Asamura H, Hishida T, Suzuki K, et al. Radiographically determined noninvasive adenocarcinoma of the lung: survival outcomes of Japan Clinical Oncology Group 0201. J Thorac Cardiovasc Surg. 2013;146(1):24–30.PubMedCrossRef
13.
Zurück zum Zitat Rusch VW, Asamura H, Watanabe H, Giroux DJ, Rami-Porta R, Goldstraw P. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. May 2009;4(5):568–77. Rusch VW, Asamura H, Watanabe H, Giroux DJ, Rami-Porta R, Goldstraw P. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. May 2009;4(5):568–77.
15.
Zurück zum Zitat Bryant A, Cerfolio RJ. Differences in epidemiology, histology, and survival between cigarette smokers and never-smokers who develop non-small cell lung cancer. Chest. 2007;132(1):185–92.PubMedCrossRef Bryant A, Cerfolio RJ. Differences in epidemiology, histology, and survival between cigarette smokers and never-smokers who develop non-small cell lung cancer. Chest. 2007;132(1):185–92.PubMedCrossRef
16.
Zurück zum Zitat Kawaguchi T, Takada M, Kubo A, et al. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol. 2010;5(5):620–30.PubMedCrossRef Kawaguchi T, Takada M, Kubo A, et al. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol. 2010;5(5):620–30.PubMedCrossRef
17.
Zurück zum Zitat Toh CK, Gao F, Lim WT, et al. Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol 20 2006;24(15):2245–51.PubMedCrossRef Toh CK, Gao F, Lim WT, et al. Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol 20 2006;24(15):2245–51.PubMedCrossRef
18.
Zurück zum Zitat Kuroda D, Sawayama H, Kurashige J, et al. Controlling Nutritional Status (CONUT) score is a prognostic marker for gastric cancer patients after curative resection. Gastric Cancer. 2018;21(2):204–12.PubMedCrossRef Kuroda D, Sawayama H, Kurashige J, et al. Controlling Nutritional Status (CONUT) score is a prognostic marker for gastric cancer patients after curative resection. Gastric Cancer. 2018;21(2):204–12.PubMedCrossRef
19.
Zurück zum Zitat Janjigian YY, McDonnell K, Kris MG, et al. Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer. Cancer. 2010;116(3):670–5.PubMedPubMedCentralCrossRef Janjigian YY, McDonnell K, Kris MG, et al. Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer. Cancer. 2010;116(3):670–5.PubMedPubMedCentralCrossRef
20.
Zurück zum Zitat Takenaka T, Inamasu E, Yoshida T, et al. Post-recurrence survival of elderly patients 75 years of age or older with surgically resected non-small cell lung cancer. Surg Today. 2016;46(4):430–6.PubMedCrossRef Takenaka T, Inamasu E, Yoshida T, et al. Post-recurrence survival of elderly patients 75 years of age or older with surgically resected non-small cell lung cancer. Surg Today. 2016;46(4):430–6.PubMedCrossRef
21.
Zurück zum Zitat Di Cello F, Flowers VL, Li H, et al. Cigarette smoke induces epithelial to mesenchymal transition and increases the metastatic ability of breast cancer cells. Mol Cancer. 2013;12:90. Di Cello F, Flowers VL, Li H, et al. Cigarette smoke induces epithelial to mesenchymal transition and increases the metastatic ability of breast cancer cells. Mol Cancer. 2013;12:90.
22.
Zurück zum Zitat Xu L, Mao XY, Fan CF, Zheng HC. MTA1 expression correlates significantly with cigarette smoke in non-small cell lung cancer. Virchows Arch. 2011;459(4):415–22.PubMedCrossRef Xu L, Mao XY, Fan CF, Zheng HC. MTA1 expression correlates significantly with cigarette smoke in non-small cell lung cancer. Virchows Arch. 2011;459(4):415–22.PubMedCrossRef
23.
Zurück zum Zitat Huynh TP, Mah V, Sampson VB, et al. Na,K-ATPase is a target of cigarette smoke and reduced expression predicts poor patient outcome of smokers with lung cancer. Am J Physiol-Lung C. 2012;302(11):L1150–8.CrossRef Huynh TP, Mah V, Sampson VB, et al. Na,K-ATPase is a target of cigarette smoke and reduced expression predicts poor patient outcome of smokers with lung cancer. Am J Physiol-Lung C. 2012;302(11):L1150–8.CrossRef
24.
Zurück zum Zitat van Osch FHM, Vlaanderen J, Jochems SHJ, et al. Modeling the complex exposure history of smoking in predicting bladder cancer: a pooled analysis of 15 case-control studies. Epidemiology (Cambridge, Mass.). 2019;30(3):458–65. van Osch FHM, Vlaanderen J, Jochems SHJ, et al. Modeling the complex exposure history of smoking in predicting bladder cancer: a pooled analysis of 15 case-control studies. Epidemiology (Cambridge, Mass.). 2019;30(3):458–65.
25.
Zurück zum Zitat Poullis M, McShane J, Shaw M, et al. Smoking status at diagnosis and histology type as determinants of long-term outcomes of lung cancer patients. Eur J Cardiothorac Surg. 2013;43(5):919–24.PubMedCrossRef Poullis M, McShane J, Shaw M, et al. Smoking status at diagnosis and histology type as determinants of long-term outcomes of lung cancer patients. Eur J Cardiothorac Surg. 2013;43(5):919–24.PubMedCrossRef
26.
Zurück zum Zitat Okamoto T, Suzuki Y, Fujishita T, et al. The prognostic impact of the amount of tobacco smoking in non-small cell lung cancer–differences between adenocarcinoma and squamous cell carcinoma. Lung cancer (Amsterdam, Netherlands). 2014;85(2):125–30.CrossRef Okamoto T, Suzuki Y, Fujishita T, et al. The prognostic impact of the amount of tobacco smoking in non-small cell lung cancer–differences between adenocarcinoma and squamous cell carcinoma. Lung cancer (Amsterdam, Netherlands). 2014;85(2):125–30.CrossRef
27.
Zurück zum Zitat Cancer Genome Atlas Research N. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489(7417):519–25. Cancer Genome Atlas Research N. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489(7417):519–25.
28.
Zurück zum Zitat Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41–50.PubMedCrossRef Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41–50.PubMedCrossRef
29.
Zurück zum Zitat Moolgavkar SH, Dewanji A, Luebeck G. Cigarette smoking and lung cancer: reanalysis of the British doctors’ data. J Ntl Cancer Inst. 15 1989;81(6):415–20.CrossRef Moolgavkar SH, Dewanji A, Luebeck G. Cigarette smoking and lung cancer: reanalysis of the British doctors’ data. J Ntl Cancer Inst. 15 1989;81(6):415–20.CrossRef
Metadaten
Titel
Prognostic Impact of Smoking Period in Patients with Surgically Resected Non-small Cell Lung Cancer
verfasst von
Shinkichi Takamori, MD, PhD
Mototsugu Shimokawa, MD, PhD
Taichi Matsubara, MD, PhD
Naoki Haratake, MD, PhD
Ryo Toyozawa, MD
Naoko Miura, MD, PhD
Masafumi Yamaguchi, MD, PhD
Takashi Seto, MD, PhD
Tetsuzo Tagawa, MD, PhD
Tatsuro Okamoto, MD, PhD
Mitsuhiro Takenoyama, MD, PhD
Yoshihiko Maehara, MD, PhD
Masaki Mori, MD, PhD
Publikationsdatum
16.07.2020
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 2/2021
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-08851-6

Weitere Artikel der Ausgabe 2/2021

Annals of Surgical Oncology 2/2021 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.